Research programme: cell therapy-modifying enzymes - Targazyme

Drug Profile

Research programme: cell therapy-modifying enzymes - Targazyme

Alternative Names: ASC-102; ASC-201; Extracellular superoxide dismutase - America Stem Cell; Fucosyltransferase - Targazyme; TZ-102

Latest Information Update: 28 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator America Stem Cell
  • Developer Targazyme
  • Class Fucosyltransferases; Oxidoreductases
  • Mechanism of Action Free radical inhibitors; Fucosyltransferase replacements; Superoxide dismutase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Haematological malignancies; Multiple sclerosis; Stroke
  • Discontinued Radiation injuries

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for preclinical development in Multiple-sclerosis in USA (IV)
  • 26 Apr 2018 Pharmacodynamics data from a preclinical trial in Cancer released by Targazyme
  • 18 Jan 2017 Targazyme has patent protection for Fucosylation technology platform in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top